Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.
Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, Kollmorgen G, Bayfield A, Wild N, Hoffman J, Ceniceros R, Dolton M, Bohórquez SMS, Hoogenraad CC, Wildsmith KR, Teng E, Monteiro C, Anania V, Yeh FL.
Schauer SP, et al. Among authors: toth b.
Alzheimers Dement. 2024 Nov 8. doi: 10.1002/alz.14346. Online ahead of print.
Alzheimers Dement. 2024.
PMID: 39513754